Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Multiple sclerosis and MyChart® messaging: a retrospective chart review evaluating its use at an academic medical center
Multiple Sclerosis
P12 - Poster Session 12 (12:00 PM-1:00 PM)
9-012

Our objective was to characterize MyChart® (Epic Systems Corporation) utilization patterns in patients with MS in our academic out-patient setting.

Tethered-messaging systems embedded in electronic health record (EHR) systems confer well-documented benefits for both patients and healthcare providers, yet they introduce unique challenges and are naturally limited. Identifying predictors of their use may provide the groundwork for optimization of these tethered-messaging systems in clinical practice, especially as they pertain to unique patient populations. Little about the usage of secure-messaging systems in patients with multiple sclerosis (MS) is known.

A retrospective cross-sectional analysis of patients within our center’s database (n=439) was performed. Inclusion criteria were >1 clinic visit and MS diagnosis. Demographic, disease-specific characteristics, use of disease-modifying therapies (DMTs) and MyChart® messaging information were extracted.

MyChart® users in our center’s database was 74% (n=324). There were statistically significant differences noted between MyChart® users and non-users. MyChart® users were more often younger (age 50.1±12.6 vs age 55±13.7), had a shorter duration since diagnosis (11.9±8.3 vs 15.8±10.8, years) and had a lower patient-determined disease steps (PDDS) (2.8±2.3 vs 3.5±2.5) than non-users. There were also statistically significant differences between MyChart® usage and DMT use. Those that were on higher-efficacy DMTs (ie. alemtuzumab, ocrelizumab, fingolimod) compared to traditional DMTs (glatiramer acetate, interferons), were more likely to have higher MyChart® usage.

EHR systems have improved healthcare delivery overall but also have presented unique challenges with their implementation, including secure-messaging systems such as MyChart®. Our study showed a majority of our patients use MyChart®, with certain factors influencing their usage. The burden-to-benefit ratio of these secure-messaging systems is still being defined. Further understanding these factors that influence MyChart® use could be leveraged in many ways including to better route work that could be delegated, thus reducing healthcare provider workload, improve professional morale and decrease healthcare provider burnout.

Authors/Disclosures
Nadia Khalil, MD (University of South Florida Morsani College of Medicine)
PRESENTER
Dr. Khalil has received personal compensation in the range of $0-$499 for serving as a Resident and Fellow Council Member with American Association of Neuromuscular & Electrodiagnostic Medicine. Dr. Khalil has received personal compensation in the range of $0-$499 for serving as a MS Mentorship Forum Participant with Foundation of the Consortium of Multiple Sclerosis Centers.
Angela Aungst No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Janice Y. Maldonado, MD (Univ of South Florida, College of Medicine) The institution of Dr. Maldonado has received research support from Genentech.
Derrick Robertson, MD Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Greenwich Biosciences. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Janssen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi Genzyme. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mallinckrodt. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Robertson has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Robertson has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Genentech. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for PRIME CME. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Janssen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Horizon. Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for McVeigh. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Mccumber. Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Goodis. The institution of Dr. Robertson has received research support from Biogen. The institution of Dr. Robertson has received research support from EMD Serono. The institution of Dr. Robertson has received research support from Jansenn. The institution of Dr. Robertson has received research support from Genentech. The institution of Dr. Robertson has received research support from Patient-Centered Outcomes Research Institute. The institution of Dr. Robertson has received research support from Novartis. The institution of Dr. Robertson has received research support from Sanofi Genzyme. The institution of Dr. Robertson has received research support from TG Therapeutics. The institution of Dr. Robertson has received research support from Prime. The institution of Dr. Robertson has received research support from Greenwich Biosciences. The institution of Dr. Robertson has received research support from Atara Biotherapeutics. The institution of Dr. Robertson has received research support from CorEvitas. The institution of Dr. Robertson has received research support from Anokion. The institution of Dr. Robertson has received research support from UCB Biosciences. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Consortium of Multiple Sclerosis Centers. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Multiple Sclerosis Association of America.